case_images: PMC7141926_01
case_images: Prior to treatment with topical INFa-2b. The lesion affects approximately 180o of the superior conjunctiva and cornea, and it partially invades the pupil
case_images: RomJOphthalmol-64-62-g001.jpg
case_images: PMC7141926_01_RomJOphthalmol-64-62-g001.jpg
case_images: F1
case_images: On exploration, the RE presented a fleshy, leukoplakia, over elevated and vascularized lesion, extending approximately over the 180o superior limbus and superior conjunctiva (from IX to III) that invaded part of the pupil (Fig. 1).
case_images: One month after topical treatment with INFa-2b. The lesion has significantly reduced in size and thickness, conjunctival leukoplakia has regressed, and pupillary axis was not affected
case_images: RomJOphthalmol-64-62-g002.jpg
case_images: PMC7141926_01_RomJOphthalmol-64-62-g002.jpg
case_images: F2
case_images: One month after treatment, the gelatinous and leukoplakia lesion diminished, showing flattening and regression of the vascularization (Fig. 2).
case_images: Six months after the initial treatment with topical INFa-2b. The lesion has disappeared
case_images: RomJOphthalmol-64-62-g003.jpg
case_images: PMC7141926_01_RomJOphthalmol-64-62-g003.jpg
case_images: F3
case_images: Given the satisfactory response to IFN-alpha-2beta, the treatment was continued up to six months of follow up, after which a complete remission of the lesion was noted (Fig. 3).